Acrosian launches AI-era biometrics CRO from veteran leadership team

Acrosian LLC launched July 22, 2026, in Princeton, New Jersey, as a biometrics contract research organization built for AI-first workflows. The new company reunites leaders from a former global biometrics CRO and says it will pair AI augmentation with GxP validation, human oversight and auditability for pharma, biotech and med device clients.

Why it matters: - Acrosian is entering a market where sponsors want faster biometrics work without losing control over quality, compliance or traceability. - The company is positioning AI as a workflow accelerator, not a replacement for expert judgment, which could matter to regulated drug and device developers.

What happened: - Acrosian LLC announced its launch on July 22, 2026, as a next-generation biometrics CRO headquartered in Princeton, New Jersey. - The company was founded by Benjamin Jackson, Soumitra Chowdhury, MBA, and Vladimir Mats, Ph.D. - The founding team previously built one of the world’s largest independent biometrics CROs, with operations across three continents, before that business was acquired. - Acrosian offers clinical data management, biostatistics, statistical programming and medical writing services to pharmaceutical, biotechnology and medical device companies. - The company is actively engaging sponsors from emerging biotechnology firms to global pharmaceutical organizations. - More information is available at the company's website.

The details: - Acrosian says its workflows are built for the AI era from the ground up rather than retrofitted onto legacy systems. - The executive team includes Benjamin Jackson as co-founder and chairman, Soumitra Chowdhury as co-founder and CEO, Vladimir Mats as co-founder and chief commercial officer, Yurii Kartashov, Ph.D., as chief research and development officer, and Aparna (Tanya) Chowdhury, CISA, CDPSE, MIT CSO, as chief audit and compliance officer. - AI-augmented workflows are developed inside a unified GxP validation framework before they become part of client delivery. - The company says human accountability, validation, auditability, security and documented oversight are built into its quality system for every implementation. - The chief audit and compliance officer leads the governance framework. - Every client deliverable remains under qualified human responsibility. - Clients will be told which AI capabilities are operational and which are still in development.

Between the lines: - The launch reflects a broader industry push to use AI in biometrics without triggering regulatory or quality concerns. - Acrosian is using its prior operating history as proof of execution while trying to differentiate on governance and transparency. - That message is aimed at sponsors who may want AI speed but still need defensible processes in regulated trials.

What's next: - Acrosian plans to support clients from individual biometrics functions through fully integrated biometrics delivery. - The company is expected to keep expanding its AI-augmented service set as more workflows clear validation. - The public-facing test will be whether sponsors accept the firm’s promise of faster delivery with documented oversight and transparent limits on AI use.